Thymosin &#x03B1;1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2019.01.011

Abstract

Abstract:

Objective

Comparative analysis of peripheral blood T lymphocyte subsets before patients treated with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) and patients after receiving EGFR-TKI monotherapy or combined with Thymosin α1 therapy.

Methods

The data of peripheral blood T lymphocyte subsets of patients receiving EGFR-TKI and EGFR-TKI combined with Thymosin α1 was collected from May 2008 to August 2018.

Results

The number of Peripheral blood CD4⁺ , CD8⁺ and CD3⁺ T lymphocyte of patients were decreased after EGFR-TKI treatment alone(P<0.05), the number of those T lymphocytes shown no difference before EGFR-TKI monotherapy and after receiving EGFR-TKI plus Thymosin α1 therapy (P>0.05).

Conclusions

EGFR-TKI could decrease the peripheral blood T lymphocyte subsets of patients treated with EGFR-TKI, thymosin α1 was able to reverse the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of patients to some extent.

Key words: Epidermal growth factor receptor tyrosine kinase inhibitor, Thymosin α1, T lymphocyte subsets

Guangkuo Zhu, Linpeng Zheng, Qiao Yang, Zhoufei Wang, Zihan Xu, Jianguo Sun, Zhengtang Chen. Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(01): 59-62.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2019.01.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2019/V12/I01/59

Figures/Tables 3

References 22

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Bray F,Ferlay J,Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
3	Herbst RS,Heymach JV,Lippman SM. Lung cancer [J]. N Engl J Med, 2008, 359(13): 1367-1380.
4	Allemani C,Weir HK,Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25，676，887 patients from 279 population-based registries in 67 countries (CONCORD-2)[J]. Lancet, 2015, 385(9972): 977-1010.
5	Rosell R,Carcereny E,Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
6	Watanabe S,Inoue A,Nukiwa T, et al. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion[J]. Anticancer Res, 2015, 35(12): 6957-6961.
7	Zhou C,Wu YL,Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
8	Han JY,Park K,Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol, 2012, 30(10): 1122-1128.
9	de Visser KE,Eichten A,Coussens LM. Paradoxical roles of the immune system during cancer development[J]. Nat Rev Cancer, 2006, 6(1): 24-37.
10	Luo Q,Gu Y,Zheng W, et al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway[J]. Toxicol Appl Pharmacol, 2011, 251(2): 130-136.
11	Danielli R,Cisternino F,Giannarelli D, et al. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy[J]. Expert Opin Biol Ther, 2018, 18(sup1): 77-83.
12	Garaci E,Pica F,Matteucci C, et al. Historical review on thymosin alpha1 in oncology: preclinical and clinical experiences[J]. Expert Opin Biol Ther, 2015, 15 Suppl 1: S31-S39.
13	Jiang J,Wang X,Tian J, et al. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials[J]. Thorac Cancer, 2011, 2(4): 213-220.
14	余荣，孙宇，蔡庆，等. α1胸腺肽减轻放射性肺损伤[J]. 中国肺癌杂志，2011, 14(3): 187-193.
15	Moody TW,Fagarasan M,Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Res, 1993, 53(21): 5214-5218.
16	Garaci E,Pica F,Serafino A, et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33.
17	Wee P,Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways[J]. Cancers (Basel), 2017, 9(5)．
18	Li M,Ong SS,Rajwa B, et al. The SH3 domain of Lck modulates T-cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1[J]. Mol Cell Biol, 2008, 28(2): 630-641.
19	Roskoski RJ. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors[J]. Pharmacol Res, 2014, 87: 42-59.
20	Knutsen AP,Freeman JJ,Mueller KR, et al. Thymosin-alpha1 stimulates maturation of CD34＋ stem cells into CD3＋4＋ cells in an in vitro thymic epithelia organ coculture model[J]. Int J Immunopharmacol, 1999, 21(1): 15-26.
21	Romani L,Bistoni F,Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J]. Blood, 2004, 103(11): 4232-4239.
22	Jennings RN,Grayson JM,Barton ES. Type I interferon signaling enhances CD8^＋ T cell effector function and differentiation during murine gammaherpesvirus 68 infection[J]. J Virol, 2014, 88(24): 14040-14049.

[1]	Gui-juan ZHAO, Shu-zhen XU, Tian ZHANG, Chun-yan SUN, Chun-yan LIU. Study on Clinical Curative Effects of Hoisting Soup in the Treatment of Children With Chronic Idiopathic Thrombocytopenic Purpura [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2012, 08(05): 597-599.
[2]	Huili Chen, Xi Liu, Shanfeng Huang, Di Shao, Jinyu Xia. T lymphocyte subsets in peripheral blood of patients with coronavirus disease 2019 [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2021, 15(02): 99-104.
[3]	Qiaoyan Lian, Ao Chen, Chunrong Ju. Progress on T lymphocyte subsets after lung transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(02): 151-155.
[4]	Shuang Xia, Min Cao, Xiang Xi. Effects of retroperitoneal laparoscopic partial nephrectomy on serum T lymphocyte subsets and prognosis and survival in elderly patients with T1b stage renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2021, 15(05): 406-410.
[5]	Xixiang Yan, Aidong Zheng, Zhenen Zhang, Guocui Pan, Yonghua Cui. Effect of thymosin α1 immunotherapy combined with anti-infection on the prognosis of severe pneumonia and possible therapeutic mechanism [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(03): 301-304.
[6]	Yanli Chen, Yuanyuan Wang, Yong Zhang, Wenjie Li. Differential expression of T lymphocyte subsets in patients with advanced non-small cell lung cancer before and after chemotherapy and its clinical significance [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 13-17.
[7]	Yanlin Tang, Feng Wang, Zigang Liu, Yuan He. Relationship between peripheral blood T lymphocyte subsets early inflammatory markers and the prognosis in elderly patients with non-small cell lung cancer after chemotherapy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(02): 97-102.
[8]	Xihui Ma, Li Xiao. Research progress in members of lymphocyte subsets [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2017, 07(03): 168-172.
[9]	Yongqing Han, Minchao Rao, Feng Fu, Kairong Huang. Shenqishiyiwei granules combined with FOLFOX4 chemotherapy for treatment of patients with advanced colorectal cancer: short-term efficacy and effect on serum IL-35, IL-37, and T lymphocyte subsets [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 400-404.
[10]	Jingjing Ma, Dandan Wu, Jixiang Zhang, Gangyan Zhu, Guozhong Chen, Yingjie Yang, Yuan Lei, Wenhao Su, Weiguo Dong. Clinical significance of changes in peripheral blood T lymphocyte subsets in patients with coronavirus disease 2019 [J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(10): 759-763.
[11]	Jianmei Zhang, Fasheng Liu, Xin Chen, Zhenhua Zhu. Significance of changes of peripheral venous blood T lymphocyte subsets and IL-6 in diagnosis and treatment of neonatal hyperbilirubinemia [J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(10): 571-575.
[12]	Lijun Meng, Qin Song, Li Shao, Jian Li. Changes and clinical significance of peripheral blood T lymphocyte subsets in systemic lupus erythematosus patients complicated with pulmonary hypertension [J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(01): 38-43.

Please choose a citation manager

Content to export

Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 3

References 22

Related Articles 12

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 3

References 22

Related Articles 12

Recommended Articles

Metrics

Comments